3 results
1. To determine the efficacy of CJM112 300 mg in chronic hidradenitis suppurativa (HS) patients, by clinical responder rate at week 16.2. To assess the safety and tolerability of CJM112 in patients with chronic hidradenitis suppurativa (HS)3. To…
The study is designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition,…
Primary objectiveThe primary objective of the study is to determine the effect of lucerastat on neuropathic pain in subjects with Fabry disease (FD).Secondary objectives* To determine the effects of lucerastat on gastro-intestinal (GI) symptoms (…